melanoma
potenti
lethal
skin
cancer
wide
thought
immunogen
natur
much
focu
cellmedi
immun
respons
limit
knowledg
exist
role
matur
b
cell
describ
approach
includ
cellbas
elisa
evalu
matur
igg
antibodi
respons
melanoma
human
peripher
blood
b
cell
observ
signific
increas
antibodi
respons
melanoma
patient
n
primari
metastat
melanoma
cell
compar
healthi
volunt
n
interestingli
detect
signific
reduct
antibodi
respons
melanoma
advanc
diseas
stage
patient
cohort
n
overal
melanoma
patientderiv
b
cell
cultur
n
compar
cultur
healthi
control
n
produc
antibodi
recogn
melanoma
cell
lastli
patientderiv
melanomaspecif
monoclon
antibodi
select
studi
antibodi
effect
kill
melanoma
cell
vitro
via
antibodymedi
cellular
cytotox
data
demonstr
presenc
matur
system
b
cell
respons
melanoma
patient
reduc
diseas
progress
ad
previou
report
tumorreact
antibodi
patient
sera
suggest
merit
futur
work
elucid
clinic
relev
activ
humor
immun
respons
cancer
malign
melanoma
fatal
form
skin
cancer
aris
malignantlytransform
melanocyt
basal
layer
epidermi
incid
melanoma
increas
acceler
rate
past
decad
amongst
fair
skin
popul
advanc
form
diseas
highli
resist
treatment
thu
urgent
need
exist
novel
therapi
earlier
diagnosi
melanoma
wide
thought
immunogen
support
clinic
observ
frequenc
spontan
tumor
regress
preval
melanoma
immunosuppress
patient
partial
success
clinicallyavail
immun
modulatori
therapi
polyclon
immun
activ
cytokin
host
adapt
immun
respons
describ
melanoma
main
focu
melanoma
specif
cell
respons
support
success
case
scenario
use
immunotherapeut
strategi
dendrit
cell
vaccin
adopt
cell
therapi
monoclon
antibodi
limit
research
focus
b
cell
specif
antibodi
produc
cancer
promot
cancer
develop
creation
proinflammatori
environ
antitumor
function
activ
matur
cell
respons
propos
potenti
role
b
cell
anim
model
cancer
may
host
immun
respons
malign
follow
immun
varieti
mechan
involv
tumor
escap
describ
understand
complex
relationship
immunosurveil
tumor
escap
patient
key
design
effect
immunotherapi
despit
wellcharacter
tumorinduc
immunomodul
immunotherapi
monoclon
antibodi
emerg
key
diagnost
therapeut
modal
standard
care
treatment
variou
cancer
antibodi
treatment
melanoma
aim
enhanc
key
pathway
cell
activ
cytotox
lymphocyteassoci
antigen
eg
ipilimumab
target
tumor
vasculatur
eg
bevacizumab
tumorassoci
antigen
eg
high
molecular
weightmelanoma
associ
antigen
hmwmaa
demonstr
promis
clinic
studi
antibodi
therefor
repres
attract
approach
treatment
melanoma
report
tumorspecif
antibodi
sera
melanoma
patient
date
back
forti
year
far
provid
valuabl
insight
immun
respons
cancer
serolog
studi
individu
melanoma
shown
patient
express
certain
tumorassoci
antigen
antibodi
antigen
convers
patient
without
antibodi
also
lack
correspond
tumor
antigen
studi
restrict
antibodi
sera
known
tumorassoci
antigen
serolog
studi
report
igg
antibodi
recogn
intracellular
melanocyt
melanomaassoci
antigen
tyrosinas
tyrosinaserel
protein
trp
melanomaassoci
glycoprotein
antigen
famili
patient
melanoma
serumresid
antibodi
antigen
enhanc
follow
polyval
melanoma
cell
vaccin
immun
patient
melanoma
suggest
melanomaassoci
antigen
may
immunogen
humor
respons
melanocyt
melanoma
antigen
may
constitut
potenti
target
immunotherapi
new
antigen
restrict
express
normal
tissu
wide
distribut
variou
cancer
includ
melanoma
discov
use
serolog
analysi
recombin
cdna
express
librari
serex
techniqu
test
tumor
mrna
autolog
patient
sera
serex
studi
human
melanoma
one
cell
line
led
discoveri
human
testi
antigen
mani
antigen
primarili
intracellular
make
less
attract
target
monoclon
antibodi
furthermor
serolog
screen
may
also
limit
tempor
dynam
sera
antibodi
evalu
reactiv
antibodi
secret
circul
b
cell
may
therefor
provid
addit
insight
serolog
evalu
interrog
longterm
memori
antitumor
system
matur
humor
respons
cancer
product
tumorspecif
antibodi
melanoma
patientderiv
b
cell
peripher
blood
tumor
report
yield
antibodi
igm
igg
class
past
studi
limit
poor
ebv
transform
effici
human
b
cell
low
product
immunoglobulin
evalu
patient
lack
effect
reproduc
method
rapidli
screen
tumorspecif
antibodi
address
limit
took
advantag
recent
advanc
grow
immort
memori
b
cell
cultur
increas
number
patient
evalu
develop
novel
screen
tool
specif
detect
tumorreact
antibodi
cell
surfac
antigen
melanoma
cell
approach
entail
cultur
patientderiv
circul
b
cell
screen
antibodi
secret
reactiv
specif
melanoma
cell
versu
melanocyt
strategi
screen
antibodi
known
antigen
evalu
antibodi
secret
sequest
serum
discret
time
rather
uniqu
aim
monitor
tumor
cellreact
igg
antibodi
produc
b
cell
cultur
elucid
breadth
longterm
matur
b
cell
repertoir
recogn
melanoma
antigen
express
surfac
cancer
cell
studi
screen
tumorreact
tumorspecif
igg
antibodi
produc
patient
healthi
individu
b
cell
cultur
allow
character
beyond
phenotyp
circul
b
cell
repertoir
individu
melanoma
clinic
correl
matur
humor
respons
diseas
progress
also
provid
exampl
demonstr
screen
may
facilit
identif
antibodi
abl
target
cancer
cell
develop
optim
cellbas
elisa
specif
detect
tumorreact
antibodi
order
obtain
robust
optim
system
detect
antitumor
antibodi
patient
figur
first
evalu
sensit
specif
igg
antibodi
melanoma
cell
surfac
antigen
hmwmaa
express
melanoma
cell
use
immunocytochemistri
cytospin
live
cell
flow
cytometri
antihmwmaa
antibodi
observ
bind
cell
melanocyt
rang
concentr
low
ngml
use
immunocytochemistri
figur
flow
cytometri
figur
b
next
compar
detect
antibodi
bound
melanoma
cell
cellbas
elisa
method
util
novel
elisa
detect
tumorspecif
antibodi
concentr
low
ngml
figur
c
demonstr
compar
sensit
flow
cytometr
immunocytochem
method
addit
valid
abil
identifi
tumorreact
antibodi
patient
cultur
compar
equal
amount
nonspecif
igg
cultur
media
figur
also
examin
potenti
applic
method
identifi
tumorspecif
antibodi
cancer
use
mammari
carcinoma
cell
line
highli
express
cell
surfac
tumorassoci
antigen
neu
trastuzumab
herceptin
tm
human
antibodi
specif
specif
detect
compar
equal
amount
control
igg
employ
method
figur
thu
demonstr
detect
antibodi
tumor
cell
antigen
sensit
specif
reproduc
manner
first
establish
b
cell
cultur
peripher
blood
melanoma
patient
studi
antibodi
respons
cancer
figur
agreement
previous
publish
report
detect
reduc
memori
b
cell
subset
melanoma
patient
melanoma
patient
healthi
volunt
b
cell
cultur
b
cell
puriti
greater
follow
ebv
transform
activ
agonist
patient
b
cell
observ
prolifer
cultur
eight
week
cell
cultur
igg
posit
b
cell
cultur
deriv
healthi
volunt
n
melanoma
patient
n
compar
mean
antibodi
titer
day
rang
mg
individu
overal
mean
mg
ci
per
cultur
aris
b
cell
per
well
therefor
establish
antibodysecret
cultur
melanoma
patient
compar
rate
igg
secret
healthi
volunt
next
investig
whether
specif
antibodi
respons
melanoma
could
detect
circul
b
cell
patient
healthi
volunt
util
cellbas
elisa
antibodysecret
b
cell
cultur
healthi
volunt
patient
n
stage
ii
n
stage
iii
n
stage
iv
evalu
reactiv
metastat
primari
melanoma
cell
rel
nonspecif
human
igg
control
calcul
fold
increas
nonspecif
human
igg
control
employ
cellbas
elisa
found
signific
increas
mean
reactiv
fold
increas
patientderiv
antibodi
cultur
n
metastat
melanoma
cell
fold
increas
ci
compar
antibodi
cultur
n
deriv
healthi
volunt
fold
increas
ci
figur
signific
increas
also
seen
mean
reactiv
patientderiv
antibodi
primari
melanoma
cell
fold
increas
ci
compar
antibodi
healthi
volunt
fold
increas
ci
figur
b
patient
cohort
thu
observ
significantli
increas
reactiv
primari
metastat
melanoma
cell
compar
healthi
volunt
examin
antibodi
respons
differ
accord
diseas
stage
studi
cohort
patient
diagnos
stage
ii
iii
iv
melanoma
tabl
evalu
reactiv
antibodi
cultur
n
patient
metastat
melanoma
cell
line
util
cellbas
elisa
patient
cohort
almost
exclus
caucasian
antibodi
reactiv
melanoma
cell
quantifi
rel
nonspecif
human
igg
control
measur
fold
increas
neg
control
patient
local
nonmetastat
stage
ii
diseas
significantli
higher
mean
antibodi
respons
fold
increas
ci
compar
confirm
metastat
diseas
stage
iii
iv
fold
increas
ci
figur
also
found
overal
signific
reduct
mean
reactiv
antibodi
secret
b
cell
cultur
melanoma
cell
stage
ii
fold
increas
ci
n
stage
iii
fold
increas
ci
n
stage
iv
patient
fold
increas
ci
n
figur
b
stage
patient
evalu
sinc
sampl
one
patient
n
b
cell
cultur
cohort
avail
includ
group
highest
mean
antibodi
reactiv
melanoma
cell
observ
patient
diagnos
stage
ii
iii
melanoma
respect
tabl
howev
observ
variat
antibodi
respons
among
individu
patient
patient
cohort
least
one
antibodyproduc
cultur
optic
densiti
valu
neg
igg
control
tabl
find
suggest
despit
signific
reduct
proport
tumorreact
antibodi
cultur
function
diseas
progress
patient
stage
group
b
cell
antibodi
recogn
tumor
cell
screen
tumorreact
antibodi
patient
b
cell
cultur
approxim
frequenc
specif
select
cultur
tumor
cell
screen
b
cell
cultur
supernat
stringent
compar
use
posit
control
monoclon
antibodi
trastuzumab
recogn
tumor
antigen
express
breast
cancer
cell
melanoma
cell
trastuzumab
select
posit
control
compar
bind
across
melanoma
cell
line
melanocyt
shown
mean
fluoresc
intens
antibodi
bind
rang
cell
figur
previou
studi
screen
tumorspecif
antibodi
select
well
greater
mean
neg
control
optic
densiti
od
three
standard
deviat
criteria
posit
tumorreact
antibodi
due
inher
variabl
cellbas
assay
potenti
identif
fals
posit
cultur
chose
stringent
criteria
antibodi
screen
compar
antibodi
produc
b
cell
posit
control
antibodi
od
posit
control
base
antibodi
select
criteria
od
posit
control
estim
b
cell
cultur
n
deriv
patient
aris
b
cell
produc
antibodi
recogn
metastat
melanoma
cell
compar
n
cultur
deriv
healthi
volunt
figur
b
healthi
volunt
individu
one
reactiv
cultur
cultur
individu
reactiv
cultur
rest
cohort
reactiv
cultur
patient
cohort
roughli
estim
frequenc
b
cell
produc
antibodi
recogn
melanoma
cell
assumpt
reactiv
antibodi
cultur
defin
od
posit
control
aris
singl
b
cell
plate
per
cultur
divid
total
number
posit
antibodi
cultur
patient
cohort
total
number
b
cell
evalu
patient
cohort
number
posit
antibodi
cultur
roughli
approxim
patient
cohort
one
b
cell
produc
antibodi
may
recogn
melanoma
cell
estim
frequenc
melanomareact
antibodyproduc
b
cell
melanoma
patient
perform
limit
dilut
analysi
select
stage
ii
patient
predict
may
high
antibodi
respons
melanoma
base
find
antibodi
respons
highest
group
figur
b
stage
ii
patient
patient
see
tabl
limit
dilut
analysi
assay
use
cellbas
elisa
estim
one
peripher
blood
b
cell
produc
antibodi
bind
melanoma
cell
figur
c
patient
frequenc
b
cell
produc
antibodi
react
melanocyt
also
evalu
b
cell
densiti
melanoma
cell
observ
compar
patient
antibodi
respons
melanocyt
melanoma
cell
suggest
much
lower
frequenc
antibodi
bind
normal
cell
origin
figur
c
left
limit
dilut
analysi
two
addit
metastat
one
primari
melanoma
cell
line
patient
yield
differ
compar
frequenc
metastat
cell
line
b
cell
cell
much
lower
frequenc
antibodi
bind
primari
melanoma
line
similar
observ
primari
melanocyt
figur
c
right
patient
data
suggest
detect
circul
b
cell
humor
respons
frequenc
metastat
melanoma
cell
lower
frequenc
normal
human
melanocyt
primari
melanoma
cell
confirm
frequenc
observ
patientderiv
circul
b
cell
repertoir
perform
addit
limit
dilut
assay
anoth
stage
ii
patient
patient
tabl
patient
estim
b
cell
produc
antibodi
bind
melanoma
cell
line
test
patient
figur
suggest
lower
compar
frequenc
estim
b
cell
patient
summari
appli
methodolog
result
suggest
tumorreact
antibodi
circul
b
cell
frequent
melanoma
patient
healthi
volunt
frequent
rang
metastat
melanoma
cell
compar
normal
melanocyt
select
patientderiv
tumorspecif
antibodi
order
evalu
reactiv
melanoma
cell
conduct
preliminari
assess
potenti
function
capabl
patientderiv
antibodi
screen
b
cell
cultur
well
select
base
stringent
criteria
od
posit
control
antibodi
use
cellbas
elisa
tumor
specif
antibodi
cultur
evalu
compar
bind
antibodi
cultur
multipl
melanoma
cell
versu
normal
cell
figur
observ
multipl
antibodi
cultur
higher
degre
bind
melanoma
cell
compar
melanocyt
patient
patient
figur
select
five
cultur
shown
figur
b
similar
result
obtain
screen
tumorspecif
cultur
differ
patient
melanoma
cell
melanocyt
posit
cultur
differ
bind
pattern
four
melanoma
cell
line
primari
human
melanocyt
detect
select
cultur
deriv
patient
shown
exampl
figur
c
reflect
specif
reactiv
differ
antibodi
rang
antigen
express
differ
level
number
melanoma
cell
line
reactiv
antigen
lowli
express
human
melanocyt
select
tumorposit
antibodi
cultur
subclon
limit
dilut
base
degre
reactiv
melanoma
cell
rel
melanocyt
figur
c
one
b
cell
cultur
patient
select
evalu
sinc
cell
cultur
supernat
observ
higher
degre
bind
cell
compar
melanocyt
elisa
figur
c
right
limit
dilut
melanomareact
b
cell
cultur
monoclon
antibodi
assess
specif
melanoma
cell
line
melanocyt
fibroblast
live
cell
flow
cytometri
figur
sinc
antibodi
avail
monoclon
dilut
addit
melanoma
cell
line
along
dermal
fibroblast
evalu
concord
cellbas
elisa
find
figur
c
clone
bound
rang
melanoma
cell
line
melanocyt
figur
antibodi
reactiv
primari
human
dermal
fibroblast
summari
evalu
specif
antibodi
melanoma
cell
versu
melanocyt
fibroblast
could
identifi
melanomaspecif
monoclon
antibodi
clone
limit
amount
monoclon
antibodi
b
cell
cultur
supernat
evalu
melanomacel
specif
abl
conduct
limit
function
investig
antibodi
use
clone
wish
assess
whether
patientderiv
antibodi
potenti
cytotox
activ
tumor
cell
test
tumor
cell
kill
potenti
antibodi
use
realtim
livedead
cell
cytotox
assay
use
target
metastat
melanoma
cell
recogn
clone
figur
support
video
experi
human
monocyt
cell
express
fcc
receptor
serv
effector
cell
melanoma
cell
use
target
cell
evalu
antibodydepend
cellular
cytotox
adcc
tumor
cell
mediat
patientderiv
igg
antibodi
test
two
monoclon
antibodi
deriv
patient
tabl
antibodi
bound
cell
melanocyt
antibodi
bind
cell
melanocyt
cell
base
elisa
prior
limit
dilut
serv
nontumorreact
control
figur
hour
cultur
ci
tumor
cell
given
melanomaspecif
antibodi
viabl
compar
ci
tumor
cell
given
nonmelanoma
specif
antibodi
figur
left
rel
tumor
cell
fluoresc
start
assay
mean
greenliv
tumor
cell
fluoresc
intens
reduc
nontumor
specif
antibodi
compar
tumorspecif
antibodi
figur
right
result
highlight
potenti
patient
deriv
tumorspecif
antibodi
kill
tumor
cell
antibodydepend
cell
cytotox
figur
b
see
video
tumor
cell
treat
tumorspecif
antibodi
also
observ
signific
p
reduct
movement
monocyt
effector
cell
contact
tumor
mm
ci
mm
compar
effector
cell
contact
tumor
mm
ci
mm
figur
c
use
nonspecif
antibodi
signific
p
differ
observ
movement
effector
cell
contact
tumor
cell
mm
ci
mm
compar
contact
tumor
cell
mm
ci
exampl
demonstr
patientderiv
tumorspecif
antibodi
capabl
engag
immun
effector
cell
antibodydepend
cellular
cytotox
tumor
cell
taken
togeth
data
suggest
system
melanomaspecif
matur
b
cell
respons
may
present
patient
melanoma
may
harbor
potenti
activ
cancer
cell
tabl
describ
approach
studi
circul
b
cellderiv
humor
immun
respons
cancer
appli
detect
tumorspecif
igg
antibodi
melanoma
patient
b
cell
strategi
potenti
appli
type
cancer
find
present
herein
complement
previou
serolog
studi
provid
ad
insight
matur
system
b
cell
respons
melanoma
first
step
evalu
tumor
reactiv
specif
patient
b
cellderiv
igg
antibodi
develop
mediumthroughput
cellbas
elisa
melanoma
cell
detect
antibodi
tumor
cell
surfac
antigen
figur
cell
allow
grow
adher
plate
prior
preserv
light
fix
formaldehyd
preserv
cell
allow
storag
access
multipl
plate
one
time
light
fixat
formalin
allow
preserv
potentiallyantigen
epitop
surfac
target
cell
previou
studi
report
cellbas
elisa
method
identifi
tumorspecif
antibodi
melanoma
tumor
cell
preserv
use
strong
fix
glutaraldehyd
known
potenti
mask
antigen
epitop
thu
compromis
recognit
antigen
antibodi
furthermor
specif
sensit
method
report
use
antibodi
known
cell
surfac
antigen
although
mani
intracellular
melanoma
associ
antigen
describ
tyrosinas
also
express
normal
melanocyt
defin
cell
surfac
antigen
high
molecular
weight
melanomaassoci
antigen
hmwmaa
report
express
surfac
melanoma
cell
antigen
show
heterogen
express
among
patient
thu
elisa
constitut
attract
tool
evalu
broad
respons
naturallyexpress
antigen
surfac
melanoma
cell
melanocyt
context
screen
methodolog
addit
potenti
advantag
unlik
assay
screen
singl
recombin
antigen
antigen
epitop
method
enabl
evalu
antibodi
repertoir
patient
multitud
cell
surfac
antigen
nativ
confirm
surfac
primari
metastat
melanoma
cell
also
melanocyt
provid
comprehens
inform
broad
preval
tumorreact
tumorspecif
antibodi
previou
studi
shown
concord
cell
lineassoci
antigen
antigen
express
correspond
tumor
make
suitabl
platform
tumorreact
antibodi
screen
thu
cell
line
provid
promis
altern
sourc
multipl
tumor
antigen
absenc
multipl
welldefin
highli
express
readili
avail
recombin
antigen
unlik
flow
cytometr
evalu
cellbas
elisa
requir
use
proteolyt
enzym
trypsin
therefor
better
preserv
cell
surfac
antigen
plate
target
cell
prepar
fix
frozen
batch
thu
allow
higher
throughput
screen
tumor
cellreact
antibodi
appli
evalu
cultur
supernat
cell
line
within
hour
principl
numer
elisa
plate
screen
rang
cell
line
multipl
supernat
sampl
process
simultan
addit
methodolog
may
potenti
tool
immunomonitor
tumorspecif
humor
respons
therapi
select
patient
like
benefit
immunotherapi
prognost
factor
link
tumorreact
humor
respons
clinic
outcom
assay
may
also
util
detect
surfac
antigen
rang
cell
type
thu
may
adapt
monitor
b
cellderiv
antibodi
repertoir
differ
diseas
context
agreement
recent
report
also
observ
reduct
peripher
blood
memori
b
cell
compart
metastat
melanoma
patient
measur
reduct
subset
memori
b
cell
patient
metastat
nonmetastat
melanoma
compar
healthi
volunt
figur
despit
reduct
circul
memori
b
cell
cohort
patientderiv
b
cell
capabl
secret
high
amount
igg
antibodi
activ
vitro
tlr
agonist
compar
antibodi
product
b
cell
healthi
individu
high
percentag
patientand
healthi
volunteerderiv
b
cell
express
igg
antibodi
within
day
cultur
b
cell
three
patient
melanoma
figur
thu
reduc
memori
b
compart
report
cancer
patient
show
melanomareact
portion
compart
remain
patient
cohort
demonstr
high
preval
melanoma
patientderiv
antibodi
produc
circul
b
cell
cancer
patient
recogn
melanoma
cell
line
figur
observ
b
cell
cultur
supernat
differ
patient
display
differenti
bind
cell
line
reflect
specif
reactiv
differ
antibodi
rang
antigen
express
differ
level
number
melanoma
cell
line
may
also
reflect
bind
antigen
lowli
express
human
melanocyt
figur
tabl
melanoma
patient
high
percentag
melanomareact
antibodyproduc
b
cell
cultur
significantli
higher
healthi
volunteerderiv
b
cell
cultur
figur
melanoma
patientderiv
b
cell
cultur
recogn
melanoma
cell
compar
cultur
healthi
volunt
figur
limit
dilut
analys
reactiv
melanoma
cell
versu
normal
melanocyt
provid
evid
support
presenc
frequenc
tumorreact
b
cell
figur
select
patient
deriv
b
antibodi
recogn
melanoma
cell
melanocyt
select
tumorreact
cultur
stage
iii
patient
patient
secret
antibodi
bound
tumor
cell
line
compar
melanocyt
elisa
figur
c
subclon
monoclon
antibodi
select
evalu
live
cell
flow
cytometri
solid
black
line
histogram
reactiv
fibroblast
melanocyt
melanoma
cell
line
igg
isotyp
control
shown
shade
grey
histogram
figur
tumorspecif
antibodi
deriv
patient
melanoma
abl
induc
tumor
cell
cytotox
two
monoclon
antibodi
evalu
vitro
use
live
cell
imag
assay
clone
bound
cell
compar
melanocyt
clone
also
patient
serv
neg
control
antibodi
experi
cell
viabil
melanoma
cell
incub
patient
blood
figur
one
stage
ii
patient
evalu
data
indic
metastat
melanoma
cell
recogn
higher
proport
b
cell
estim
averag
matur
b
cell
compar
primari
melanoma
cell
melanocyt
although
cohort
patient
measur
reactiv
b
cell
cultur
metastat
primari
melanoma
cell
line
figur
take
consider
expect
variabl
immun
respons
among
patient
array
tumor
antigen
patient
may
expos
observ
b
cell
two
patient
stage
ii
melanoma
yield
compar
reactiv
metastat
melanoma
cell
estim
patient
b
cell
patient
indic
presenc
support
preval
circul
melanomareact
b
cell
compart
tumorreact
antibodi
detect
melanoma
patient
studi
antibodi
respons
deriv
circul
b
cell
melanoma
cell
decreas
advanc
diseas
stage
figur
previou
serolog
studi
report
serumresid
antibodi
tumor
cell
melanoma
patient
evid
serum
antibodi
diminish
patient
advanc
diseas
unclear
whether
consequ
sequest
antibodi
tumor
increas
tumor
burden
patient
find
provid
insight
demonstr
presenc
circul
longterm
matur
b
cell
respons
cancer
diseas
stage
broad
rang
natur
express
antigen
surfac
primari
metastat
tumor
cell
also
report
decreas
frequenc
tumorreact
antibodyproduc
b
cell
advanc
diseas
thu
support
premis
mechan
immun
toler
rather
adsorpt
antibodi
tumor
advanc
diseas
set
may
also
explain
reduct
one
limit
may
aris
screen
antibodi
mostli
metastat
melanoma
cell
possibl
observ
may
reflect
reactiv
antigen
present
primari
diseas
may
preserv
upregul
advanc
diseas
set
find
may
account
reactiv
tumor
antigen
lost
diseas
progress
reduc
reactiv
melanoma
observ
may
impli
weaken
immun
respons
subset
antigen
surfac
melanoma
cell
anoth
explan
observ
may
advanc
diseas
matur
circul
b
cell
home
increas
tumor
site
thu
reduc
circul
tumorreact
b
cell
compart
patient
futur
studi
aim
monitor
local
b
cell
respons
tumor
may
provid
clue
dynam
matur
b
cell
respons
system
local
level
cancer
thu
despit
wellknown
weaken
host
immun
respons
diseas
progress
abl
detect
melanomareact
antibodi
patient
circul
b
cell
impli
although
matur
humor
immun
respons
weaken
respons
form
matur
memori
b
cell
may
persist
howev
work
elucid
potenti
immunomodulatori
role
b
cell
immun
cell
cancer
includ
product
b
cell
popul
subset
merit
consider
although
report
presenc
antitumor
antibodi
produc
patient
memori
b
cell
cell
stimul
ex
vivo
secret
antibodi
clear
whether
tumor
antigenreact
b
cell
activ
patient
secret
antibodi
whether
humor
respons
capabl
exert
benefici
antitumor
activ
patient
vivo
patient
cohort
differ
diseas
stage
studi
abl
draw
conclus
regard
relationship
tumor
cell
reactiv
clinic
diseas
progress
short
term
month
year
follow
associ
particular
diseas
treatment
regim
howev
monitor
matur
memori
b
cell
antibodi
repertoir
togeth
clinic
outcom
patient
long
period
time
may
help
identifi
correl
melanomareact
matur
memori
b
cell
respons
diseas
progress
addit
futur
studi
may
help
identifi
particular
compon
humor
respons
may
hold
clinic
relev
elucid
potenti
merit
monitor
respons
relat
therapi
evalu
humor
respons
prognost
factor
clinic
outcom
import
question
therefor
relat
whether
patientderiv
matur
b
cell
respons
function
capabl
potent
activ
immun
effector
cell
cancer
measur
capac
one
antibodi
clone
kill
tumor
cell
antibodi
clone
deriv
patient
stage
iii
diseas
patient
tabl
observ
bind
fibroblast
melanocyt
bound
proport
melanoma
cell
line
test
figur
antibodi
tumorassoci
antigen
attack
tumor
cell
via
number
mechan
includ
induct
apoptosi
tumor
cell
engag
fc
receptor
immun
cell
antibodi
approv
treatment
cancer
shown
function
one
mechan
strategi
yield
fulli
human
monoclon
antibodi
matter
month
limit
amount
antibodi
could
produc
b
cell
perform
function
studi
evalu
reactiv
patientderiv
melanoma
tumor
howev
suffici
quantiti
evalu
whether
patientderiv
melanoma
tumorspecif
monoclon
antibodi
could
mediat
antibodi
depend
cellular
cytotox
adcc
presenc
monocyt
effector
cell
tumor
cell
use
realtim
live
cell
imag
assay
show
tumorspecif
clone
capabl
mediat
adcc
vitro
addit
measur
restrict
movement
monocyt
effector
cell
contact
tumorspecif
antibodyco
tumor
cell
provid
evid
adcc
figur
preliminari
assess
provid
promis
clue
potenti
activ
matur
b
cell
respons
melanoma
may
present
patient
exampl
possibl
recent
report
yuan
et
al
demonstr
administr
antibodi
ipilimumab
led
serolog
enhanc
antibodi
testi
antigen
ny
human
monocyt
cell
compar
sampl
treat
antibodi
hour
left
error
bar
repres
confid
interv
mean
fluoresc
intens
tumor
cell
prelabel
live
cell
dye
calcein
incub
cell
antibodi
measur
min
time
point
right
b
fluoresc
imag
live
cell
cytotox
assay
minut
interv
live
calcein
amlabel
melanoma
tumor
cell
green
incub
antibodi
cell
blue
cell
death
evalu
red
incorpor
ethidium
incorpor
red
tumor
cell
observ
magnif
scale
bar
mm
c
movement
cell
track
measur
two
hour
compar
cell
contact
contact
tumor
cell
p
movement
indic
track
line
red
yellow
origin
posit
cell
hour
magnif
scale
bar
mm
patient
respond
antibodi
therapi
therefor
conceiv
matur
b
cell
compart
could
enhanc
immunotherapeut
approach
monitor
humor
respons
therapeut
may
clinic
relev
har
cancerspecif
antibodi
repertoir
cancer
patient
use
methodolog
describ
herein
may
also
potenti
offer
altern
strategi
yield
igg
antibodi
cancer
antigen
recent
advanc
report
traggiai
et
al
evalu
monoclon
antibodi
human
memori
b
cell
yield
fullyhuman
virusneutr
antibodi
therapeut
relev
infecti
diseas
contribut
dissect
humor
memori
respons
vaccin
focu
b
cell
cancer
patient
melanoma
patient
analyz
system
humor
respons
cancer
demonstr
presenc
tumorreact
tumorspecif
antibodi
approach
may
offer
advantag
approach
phage
display
yield
vivo
affinitymatur
human
antibodi
natur
pair
heavi
light
chain
patientderiv
monoclon
antibodi
bound
melanoma
cell
line
evalu
compar
melanocyt
suggest
antibodi
may
protein
overexpress
mutat
surfac
cancer
cell
light
efficaci
trastuzumab
antigen
express
breast
cancer
clinicallyvalid
therapeut
tool
treatment
equival
proport
breast
cancer
patient
select
antibodi
bind
portion
cell
line
may
merit
character
although
clinic
signific
matur
memori
b
cell
express
antibodi
recogn
tumor
cell
patient
remain
elucid
antibodi
deriv
cell
introduc
passiv
immunotherapi
therapeuticallyrelev
dose
use
trastuzumab
patient
breast
cancer
merit
investig
potenti
relev
melanoma
potenti
futur
benefit
screen
patientderiv
b
cell
tumorreact
antibodi
may
identif
novel
cell
surfac
tumor
antigen
futur
evalu
clone
includ
sequenc
analysi
express
clone
allow
analys
specif
melanoma
tumor
antigen
identif
thorough
function
assess
data
provid
addit
understand
matur
b
cell
respons
melanoma
evalu
antibodi
deriv
circul
b
cell
cancer
patient
preval
matur
humor
respons
cancer
cell
patient
well
capac
patientderiv
antibodi
activ
effector
cell
melanoma
cell
indic
potenti
function
signific
humor
immun
respons
cancer
specimen
patient
healthi
volunt
collect
inform
written
consent
work
conduct
strict
accord
studi
design
approv
guy
research
ethic
committe
st
thoma
hospit
london
uk
obtain
inform
consent
peripher
blood
isol
healthi
volunt
n
patient
melanoma
n
patient
stage
classifi
accord
american
joint
committe
cancer
melanoma
stage
classif
criteria
b
cell
isol
neg
select
use
rosetteseph
b
cell
enrich
cocktail
stem
cell
technolog
vancouv
canada
accord
manufactur
instruct
b
cell
puriti
assess
flow
cytometri
stain
matur
b
cell
cell
monocyt
plasmacytoid
dendrit
cell
use
fluorescentlylabel
monoclon
antibodi
bd
bioscienc
oxford
uk
figur
flow
cytometri
experi
conduct
either
facsaria
facscanto
bd
bioscienc
flow
cytometr
data
analyz
use
flow
jo
tree
star
ashland
b
cell
plate
cell
per
well
well
ubottom
micropl
nunc
rochest
ny
along
cell
per
well
irradi
gy
qualit
detect
tumorspecif
antibodi
immunocytochemistri
perform
centrifug
cell
use
shandon
cytospinh
cytocentrifug
thermo
fisher
scientif
waltham
onto
glass
slide
cell
fix
formalin
antibodi
recogn
human
high
molecular
weight
melanomaassoci
antigen
antihmwmaa
clone
invitrogen
carlsbad
ca
incub
overnight
detect
follow
hour
incub
horseradish
peroxidaseconjug
antiigg
fcspecif
antibodi
dilut
tri
buffer
salin
sigma
dorset
uk
slide
stain
dab
chromogen
substrat
dako
eli
uk
minut
wash
counterstain
mayer
hematoxlin
merck
darmstadt
germani
one
minut
dehydr
mount
dpx
mountant
sigma
prior
assess
antibodi
bound
cell
surfac
antigen
also
detect
live
cell
flow
cytometri
adher
cell
detach
use
stemproh
accutaseh
cell
disassoci
solut
gibco
incub
cell
per
sampl
antibodi
isotyp
control
cell
cultur
supernat
minut
antibodi
bound
cell
detect
use
fitcconjug
antiigg
fcspecif
antibodi
jackson
immunoresearch
bind
tumorspecif
antibodi
cell
compar
excess
isotyp
control
igg
antibodi
jackson
immunoresearch
bind
trastuzumab
across
melanoma
cell
line
primari
human
melanocyt
evalu
subtract
mean
fluoresc
intens
mfi
valu
equal
amount
isotyp
control
evalu
repres
three
experi
develop
employ
novel
cellbas
elisa
identifi
melanomareact
antibodi
adher
cell
interest
plate
cell
per
ml
appropri
media
well
flat
bottom
tissu
cultur
plate
corn
corn
ny
grown
monolay
co
confluenc
cell
lightli
fix
formaldehyd
hank
buffer
salt
solut
plate
wrap
foil
place
freezer
day
assay
day
assay
plate
thaw
minut
wash
time
pb
block
nonfat
milkpb
solut
hour
remov
block
solut
ml
cultur
supernat
tumorspecif
antibodi
dilut
nonfat
milkpb
solut
ad
well
plate
incub
minut
room
temperatur
orbit
shaker
plate
wash
time
pb
tween
pbst
bind
antibodi
cell
surfac
protein
detect
follow
minut
incub
goat
antihuman
horseradish
peroxidaselabel
f
ab
fcspecif
antibodi
jackson
immunoresearch
west
grove
pa
dilut
milkpbst
room
temperatur
orbit
shaker
well
wash
time
pbst
color
reaction
develop
minut
opd
sigma
od
measur
elisa
reader
bmg
labtech
offenburi
germani
nm
refer
wavelength
nm
plate
contain
triplic
well
posit
control
antibodi
trastuzumab
genentech
south
san
francisco
ca
neg
control
antibodi
nonspecif
human
igg
jackson
immunoresearch
concentr
ngml
dilut
media
supplement
fetal
calf
serum
bind
trastuzumab
cell
background
od
valu
neg
nonspecif
human
igg
control
antibodi
form
criteria
inclus
readout
studi
sinc
limit
volum
cultur
supernat
cultur
assay
repeat
suffici
cultur
supernat
avail
confirm
reproduc
readout
use
cellbas
elisa
patient
healthi
volunt
antibodi
respons
assess
use
cellbas
elisa
evalu
reactiv
supernat
b
cell
cultur
tumor
cell
rel
neg
posit
control
antibodi
order
compar
antitumor
antibodi
respons
metastat
primari
melanoma
cell
patient
healthi
volunt
among
patient
group
optic
densiti
od
normal
use
follow
formula
fold
increaseo
ptical
densiti
b
cell
cultur
supernat
mean
optic
densiti
non
specif
igg
addit
calcul
use
normal
elisa
result
among
multipl
melanoma
cell
line
primari
melanocyt
order
evalu
tumor
specif
antibodi
evalu
presenc
estim
frequenc
tumorreact
antibodi
select
well
od
valu
od
posit
control
antibodi
compar
percentag
posit
cultur
across
patient
od
valu
normal
posit
control
evalu
mean
posit
control
od
assign
rel
absorb
plate
b
cell
cultur
convert
od
unit
rel
absorb
cultur
well
rel
absorb
valu
greater
melanoma
cell
melanocyt
select
criteria
also
appli
limit
dilut
assay
estim
percentag
nonreact
b
cell
cultur
well
limit
dilut
assay
b
cell
plate
differ
densiti
rang
b
cell
percentag
nonreact
cultur
calcul
differ
patient
cell
line
way
approxim
frequenc
b
cell
produc
melanomareact
antibodi
use
poisson
distribut
tumorkil
potenti
patientderiv
monoclon
antibodi
assess
one
tumorspecif
antibodi
anoth
antibodi
recogn
tumor
cell
deriv
patient
patient
antibodi
simultan
evalu
use
threecolor
fluoresc
live
cell
imag
cytotox
assay
cell
plate
overnight
cell
per
well
cultur
plate
corn
use
livedeadh
viabilitycytotox
kit
molecular
probe
eugen
live
tumor
cell
label
calcein
minut
prior
cytotox
assay
wash
rpmi
supplement
fc
penicillin
streptomycin
resuspend
media
contain
mm
ethidium
ethidium
incorpor
dna
dead
cell
serv
label
cell
death
assay
monocyt
cell
express
fcc
receptor
use
immun
effector
cell
ratio
effector
tumor
cell
monocyt
incub
antibodi
minut
stain
celltrack
tm
blue
dye
molecular
probe
wash
ad
calcein
amlabel
tumor
cell
cultur
contain
ethidium
sampl
incub
imag
captur
everi
minut
two
hour
humidifi
temperatur
control
chamber
use
zeiss
axiovert
microscop
equip
ldplanneofluar
object
axiovis
softwar
system
carl
zeiss
jena
germani
follow
incub
fluoresc
intens
calcein
amposit
live
tumor
cell
well
incorpor
ethidium
cell
measur
cell
death
assess
nisel
br
softwar
nikon
movement
effector
cell
cultur
track
analyz
use
imari
softwar
bitplan
zurich
switzerland
descript
statist
gener
examin
distribut
melanomareact
b
cell
cultur
patient
includ
mean
confid
interv
maximum
reactiv
melanoma
cell
twosid
student
test
use
compar
mean
reactiv
antibodi
cultur
deriv
melanoma
patient
healthi
volunt
primari
metastat
melanoma
cell
line
compar
antibodi
respons
patient
nonmetastat
metastat
diseas
oneway
anova
use
compar
antibodi
reactiv
metastat
melanoma
cell
line
among
b
cell
cultur
deriv
patient
stage
ii
iii
iv
diseas
tukey
post
hoc
comparison
test
twosid
student
test
use
compar
antibodymedi
tumor
cell
kill
tumorspecif
nonspecif
monoclon
antibodi
deriv
patient
twosid
student
test
also
employ
compar
movement
immun
effector
cell
preincub
antibodi
contact
tumor
cell
movement
immun
cell
contact
tumor
cell
statist
analys
perform
use
graphpad
prism
softwar
version
graphpad
san
diego
ca
error
bar
figur
repres
confid
interv
video
realtim
livecel
cytotox
assay
melanomaspecif
antibodi
avi
video
realtim
livecel
cytotox
assay
nonmelanomaspecif
antibodi
neg
control
video
video
file
show
realtim
cytotox
assay
video
show
realtim
function
data
melanomaspecif
patient
deriv
antibodi
observ
kill
melanoma
cell
video
show
ident
assay
shown
video
use
nonmelanoma
specif
antibodi
deriv
patient
neg
control
assay
live
tumor
cell
label
green
live
cell
dye
monocyt
cell
label
blue
cell
death
indic
incorpor
red
ethidium
incorpor
frame
video
also
display
figur
b
